Menu
Menu
Jemperli(Dostarlimab-gxly) is a prescription medication used to treat patients with certain types of advanced or recurrent endometrial cancer. If you have question, please e-mail Allevaire Indian Team or call Allevaire India on +91-9818274099 (Mr. Kamal Kaushal) for further details.
Jemperli (Dostarlimab-gxly) is a prescription medication used for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test. It is also used for the treatment of adult patients with endometrial cancer that has progressed on or following prior treatment with platinum-containing chemotherapy, as well as for the treatment of patients with advanced or recurrent non-small cell lung cancer (NSCLC) with PD-L1 expression ≥ 50% as determined by an FDA-approved test, whose disease has not progressed after platinum-based chemotherapy. JEMPERLI works by blocking the PD-1 pathway, a pathway that suppresses the immune system’s ability to fight cancer cells.
Jemperli (Dostarlimab-gxly) suppliers in India. Allevaire India New Delhi, INDIA.
Alleviare Life sciences Pvt. Ltd. is a consulting pharmaceutical company specializing in providing medicines under Named Patient Program/Manage Access Program. Named Patient Program/ Manage Access Program is a program designed by the government of India and governments of many countries worldwide for patients who have exhausted the treatment options available in their respective countries and are in need of the latest medicines that are available in countries of Europe and USA.
The order for JEMPERLI (Dostarlimab-gxly) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
JEMPERLI is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test. It is also indicated for the treatment of adult patients with endometrial cancer that has progressed on or following prior treatment with platinum-containing chemotherapy, as well as for the treatment of patients with advanced or recurrent non-small cell lung cancer (NSCLC) with PD-L1 expression ≥ 50% as determined by an FDA-approved test, whose disease has not progressed after platinum-based chemotherapy.
Medicine Name: JEMPERLI
Generic Name: Dostarlimab-gxly
Approval Date: April 22, 2021
Company Name: GlaxoSmithKline LLC
Jemperli (Dostarlimab-gxly) is available.
Get In Touch
ALS helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Jemperli (Dostarlimab-gxly) on prescription and Import License in Patient’s Name only.
For foreign countries patients, Jemperli (Dostarlimab-gxly) can be made available in Send your inquiry to find Jemperli (Dostarlimab-gxly) in China, Cambodia, Indonesia the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For Jemperli (Dostarlimab-gxly) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Visit Us:
MEZZANINE FLOOR, S-9, GREEN PARK EXTENSION, New Delhi,
South Delhi, Delhi, 110016
Call Us:
+91-9818274099
Write Us:
kamal@alleviarelife.com
